Brief Summary:

Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or have received prior vaccination with an mRNA (messenger ribonucleic acid) vaccine for the prevention of COVID-19.

Part 2: This phase will assess the efficacy of prophylactic VXA-CoV2-1.1-S against confirmed COVID-19 occurring from 7 days after second dose with a repeat-dose vaccination schedule in healthy adults compared to placebo. Safety and immunogenicity of VXA-CoV2-1.1-S will also be evaluated in this phase.

As the weather gets cooler and winter approaches, doctors are predicting a spike in COVID-19 cases and more hospitalizations which could put emergency departments at risk of being overwhelmed again.

California has begun positioning equipment and locking in contracts with temporary health care workers in preparation for another possible winter surge of coronavirus cases, Gov. Gavin Newsom said Wednesday.